Bone metabolism in male patients with type 2 diabetes

Achemlal, L.; Tellal, Saida; Rkiouak, F.; Nouijai, A.; Bezza, A.; Derouiche, El Mostapha; Ghafir, D.; Maghraoui, A. El

doi:10.1007/s10067-004-1070-9

Cited by 93 publications

(80 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The association between DM and low bone turnover has recently been reported [22,23,24,25]. In the present study, mean serum osteocalcin was significantly lower in patients with FPG ≥100 mg/dl and in diabetic patients when compared to the patients with normal blood glucose.…”

Section: Discussionsupporting

confidence: 58%

Metabolic Syndrome and Central Fat Distribution Are Related to Lower Serum Osteocalcin Concentrations

Magalhães

Magalhães²,

Diniz³

et al. 2013

Ann Nutr Metab

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate the association of serum osteocalcin with the metabolic syndrome (MS) in men and premenopausal women. Methods: 14 middle-aged men and 44 premenopausal women were evaluated. MS was defined according to the International Diabetes Federation criteria. Anthropometric data were collected and serum osteocalcin, serum C-telopeptide (CTX), fasting plasma glucose (FPG) and lipid profile measured. Results: The mean age was 41.07 ± 8.4 years and did not differ between patients with and without MS. Mean osteocalcin was significantly lower in patients with MS (11.18 ± 4.62 vs. 15.09 ± 5.05, p = 0.003) and decreased significantly with the rise in the number of criteria for diagnosis of MS. There were no significant differences in serum CTX between the two groups. Serum osteocalcin was lower in patients with body mass index (BMI) ≥25 (p = 0.038) and FPG ≥100 mg/dl (p = 0.024), and in hypertensive (p = 0.013) and diabetic patients (p = 0.036), and was inversely associated with BMI (p = 0.024), waist circumference (WC) (p = 0.024), FPG (p = 0.007) and systolic blood pressure (SBP) (p = 0.037). Conclusion: This study showed that lower serum osteocalcin is associated with the presence of MS and that osteocalcin is inversely associated with BMI, WC, FPG and SBP, suggesting that osteocalcin plays a part in the development of MS.

show abstract

Section: Discussionsupporting

confidence: 58%

Metabolic Syndrome and Central Fat Distribution Are Related to Lower Serum Osteocalcin Concentrations

Magalhães

Magalhães²,

Diniz³

et al. 2013

Ann Nutr Metab

View full text Add to dashboard Cite

show abstract

“…Another marker of bone formation, osteocalcin, particularly the undercarboxylated form, has been implicated in the regulation of insulin secretion (24). However, measurements of serum osteocalcin in patients with T2DM have provided conflicting results showing either no change or decrease (23,25,26,27,28,29). We did not measure serum osteocalcin, but a significant positive relationship with serum P1NP has been previously reported in patients with T2DM (23,28).…”

Section: Discussionmentioning

confidence: 87%

Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus

Lierop

Hamdy

Meer

et al. 2012

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Patients with type 2 diabetes mellitus (T2DM) have an increased risk of fractures and thiazolidinediones (TZDs) increase this risk. TZDs stimulate the expression of sclerostin, a negative regulator of bone formation, in vitro. Abnormal sclerostin production may, therefore, be involved in the pathogenesis of increased bone fragility in patients with T2DM treated with TZDs. Methods: We measured serum sclerostin, procollagen type 1 amino-terminal propeptide (P1NP), and carboxy-terminal cross-linking telopeptide of type I collagen (CTX) in 71 men with T2DM treated with either pioglitazone (PIO) (30 mg once daily) or metformin (MET) (1000 mg twice daily). Baseline values of sclerostin and P1NP were compared with those of 30 healthy male controls. Results: Compared with healthy controls, patients with T2DM had significantly higher serum sclerostin levels (59.9 vs 45.2 pg/ml, P!0.001) but similar serum P1NP levels (33.6 vs 36.0 ng/ml, PZ0.39). After 24 weeks of treatment, serum sclerostin levels increased by 11% in PIO-treated patients and decreased by 1.8% in MET-treated patients (PZ0.018). Changes in serum sclerostin were significantly correlated with changes in serum CTX in all patients (rZ0.36, PZ0.002) and in PIO-treated patients (rZ0.39, PZ0.020), but not in MET-treated patients (rZ0.17, PZ0.31). Conclusions: Men with T2DM have higher serum sclerostin levels than healthy controls, and these levels further increase after treatment with PIO, which is also associated with increased serum CTX. These findings suggest that increased sclerostin production may be involved in the pathogenesis of increased skeletal fragility in patients with T2DM in general and may specifically contribute to the detrimental effect of TZDs on bone.

show abstract

“…The use of biochemical markers of bone turnover has shown promise for the evaluation and monitoring of changes in bone metabolism during chronic diseases or therapy, 1 however there are few crosssectional reports available on bone turnover markers in patients with type 2 diabetes. 11,12 In the present prospective, longitudinal study, the effects of metabolic control with respect to HbA 1c levels in type 2 diabetes on biochemical markers of bone turnover were investigated. We found a decrease in the bone turnover markers for bone resorption and bone formation, and a positive correlation between glycaemic control and bone turnover markers.…”

Section: Biochemical Markers In Type 2 Diabetesmentioning

confidence: 99%

Bone Turnover Markers in Patients with Type 2 Diabetes and Their Correlation with Glycosylated Haemoglobin Levels

Capoglu

Özkan

et al. 2008

J Int Med Res

View full text Add to dashboard Cite

The aim of this prospective, longitudinal study was to investigate, over a period of 12 months, the effects of metabolic control on bone turnover markers in patients with type 2 diabetes mellitus. The study included 17 male and 18 female patients with type 2 diabetes, aged 37 -66 years. Mean follow-up period was 12 ± 1.2 months. Mean glycosylated haemoglobin (HbA 1C ) levels were 10.6% ± 1.6% at the start of the study and decreased to 7.7% ± 1.0% by the end of the study. Levels of the bone resorption markers, urinary deoxypyridinoline and N-telopeptide, were 28.6 ± 11.6 nmol/mmol creatinine and 93.6 ± 13.7 nmol bone collagen equivalents [BCE]/mmol creatinine, respectively, at the start of the study, and decreased significantly to 17.9 ± 7.1 nmol/mmol creatinine and 67.8 ± 12.8 nmol BCE/mmol creatinine, respectively, by the end of the study. Bone formation parameters also significantly decreased in parallel with HbA 1c levels over the study period. It is concluded that effective management of metabolic disorder in patients with type 2 diabetes plays an important contribution to bone turnover improvement.

show abstract

Bone metabolism in male patients with type 2 diabetes

Cited by 93 publications

References 17 publications

Metabolic Syndrome and Central Fat Distribution Are Related to Lower Serum Osteocalcin Concentrations

Metabolic Syndrome and Central Fat Distribution Are Related to Lower Serum Osteocalcin Concentrations

Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus

Bone Turnover Markers in Patients with Type 2 Diabetes and Their Correlation with Glycosylated Haemoglobin Levels

Contact Info

Product

Resources

About